Advicenne S.A. (EPA:ALDVI)

Market Cap	21.74M
Revenue (ttm)	5.73M
Net Income (ttm)	-6.46M
Shares Out	12.28M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,158
Average Volume	11,219
Open	1.770
Previous Close	1.770
Day's Range	1.724 - 1.770
52-Week Range	0.827 - 2.900
Beta	1.22
RSI	53.60
Earnings Date	Sep 18, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2024, Advicenne's revenue was 5.73 million, an increase of 75.29% compared to the previous year's 3.27 million. Losses were -6.46 million, -8.06% less than in 2023.